Assessment of exposure of metabolites in preclinical species and humans at steady state from the single-dose radiolabeled absorption, distribution, metabolism, and excretion studies: A case study

Drug Metabolism and Disposition

Volumn 40, Issue 7, 2012, Pages 1308-1320

  Prakash, Chandra ^a   Li, Zhaoyang ^a,c   Orlandi, Cesare ^b   Klunk, Lewis ^a  

^a BIOGEN   (United States)

^b Cardiokine Inc   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [2 CHLORO 4 [5 FLUORO 2 METHYL BENZOYLAMINO] BENZOYLAMINO] BENZYL] 1H PYRROLE 2 CARBOXYLIC ACID; 2 [2 CHLORO 4 [5 FLUORO 2 METHYL BENZOYLAMINO] BENZOYLAMINO] BENZOIC ACID; BENZAMIDE DERIVATIVE; CARBON 14; DRUG METABOLITE; LIXIVAPTAN; N [3 CHLORO 4 (3 OXO 2,3 DIHYDRO 1H,5H BENZO[3]PYRROLO[1,2 A][1,4]DIAZEPINE 10 CARBNONYL)PHENYL] 5 FLUORO 2 METHYL BENZAMIDE; N [3 CHLORO 4 (3 OXO 5,10,11,11A DIHYDRO 3H BENZO[E]PYRROLO[1,2 A][1,4]DIAZEPINE 10 CARBNONYL)PHENYL] 5 FLUORO 2 METHYL BENZAMIDE; UNCLASSIFIED DRUG; WAY 137930; WAY 138451; WAY 138758; WAY 141624;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CASE STUDY; CLINICAL STUDY; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; ISOTOPE LABELING; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RADIATION DETECTOR; RADIOACTIVITY; SPRAGUE DAWLEY RAT; STEADY STATE; TOXICITY TESTING;

ABSORPTION; ADOLESCENT; ADULT; ANIMALS; AREA UNDER CURVE; BENZAMIDES; CARBON RADIOISOTOPES; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; FEMALE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; METABOLOME; MIDDLE AGED; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; YOUNG ADULT;

EID: 84862665184     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.044933     Document Type: Article

References (28)

1. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, and Schrier RW (2006) Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 47:1615-1621.
2. Albright JD, Reich MF, Delos Santos EG, Dusza JP, Sum FW, Venkatesan AM, Coupet J, Chan PS, Ru X, Mazandarani H, et al. (1998) 5-Fluoro-2-methyl-N-[4- (5H-pyrrolo[2,1-c]- [1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl] benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem 41:2442-2444.
3. Ashwell MA, Bagli JF, Caggiano TJ, Chan PS, Molinari AJ, Palka C, Park CH, Rogers JF, Sherman M, Trybulski EJ, et al. (2000) The design, synthesis and physical chemical properties of novel human vasopressin V2-receptor antagonists optimized for parenteral delivery. Bioorg Med Chem Lett 10:783-786.
4. Baillie TA, Cayen MN, Fouda H, Gerson RJ, Green JD, Grossman SJ, Klunk LJ, LeBlanc B, Perkins DG, and Shipley LA (2002) Drug metabolites in safety testing. Toxicol Appl Pharmacol 182:188-196.
5. Chan PS, Coupet J, Park HC, Lai F, Hartupee D, Cervoni P, Dusza JP, Albright JD, Ru X, Mazandarani H, et al. (1998) VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 449:439-443.
6. Dalvie D, Zhang C, Chen W, Smolarek T, Obach RS, and Loi CM (2010) Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. Drug Metab Dispos 38:641-654.
7. Davis-Bruno KL and Atrakchi A (2006) A regulatory perspective on issues and approaches in characterizing human metabolites Chem Res Toxicol 19:1561-1563.
8. Decaux G (2001) Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 138:18-21.
9. Gao H, Deng S, and Obach RS (2010) A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments. Drug Metab Dispos 38:2147-2156.
10. Guyader D, Patat A, Ellis-Grosse EJ, and Orczyk GP (2002) Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 36:1197-2052.
11. Humphreys WG and Unger SE (2006) Safety assessment of drug metabolites: characterization of chemically stable metabolites. Chem Res Toxicol 19:1564-1569.
12. Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, and Evans DC (2009) Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol 22:280-293.
13. Ma S, Li Z, Lee KJ, and Chowdhury SK (2010) Determination of exposure multiples of human metabolites for MIST assessment in preclinical safety species without using reference standards or radiolabeled compounds. Chem Res Toxicol 23:1871-1873.
14. Molinari AJ, Trybulski EJ, Bagli J, Croce S, Considine J, Qi J, Ali K, Demaio W, Lihotz L, and Cochran D (2007) Identification and synthesis of major metabolites of Vasopressin V2- receptor agonist WAY-151932, and antagonist, Lixivaptan. Bioorg Med Chem Lett 17:5796-5800.
15. Muralidharan G, Meng X, DeCleene SA, Cevallos WH, Fruncillo R, Hicks D, and Orczyk GP (1999) Pharmacokinetics and pharmacodynamics of a novel vasopressin receptor antagonist, VPA-985, in healthy subjects. Clin Pharmacol Ther 65:189.
16. Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, Davies MH, Gemzik B, Christ DD, Krahn DF, et al. (2000) The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 169:102-113.
17. Penner NA, Ho G, Bercovici A, Chowdhury SK, and Alton KB (2010) Identification of two novel metabolites of SCH 486757, a nociceptin/orphanin FQ peptide receptor agonist, in humans. Drug Metab Dispos 38:2067-2074.
18. Penner N, Klunk LJ, and Prakash C (2009) Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos 30:185-203.
19. Penner N, Xu L, and Prakash C (2012) Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25:513-531.
20. Prueksaritanont T, Lin JH, and Baillie TA (2006) Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites Toxicol Appl Pharmacol 217:143-152.
21. Ramanathan R, Zhong R, Blumenkrantz N, Chowdhury SK, and Alton KB (2007) Response normalized liquid chromatography nanospray ionization mass spectrometry. J Am Soc Mass Spectrom 18:1891-1899.
22. Robison TW and Jacobs A (2009) Metabolites in safety testing. Bioanalysis 1:1193-1200.
23. Smith DA and Obach RS (2006) Metabolites and safety: what are the concerns, and how should we address them? Chem Res Toxicol 19:1570-1579.
24. Smith DA, Obach RS, Williams DP, and Park BK (2009) Clearing the MIST (metabolites in safety testing) of time: the impact of duration of administration on drug metabolite toxicity. Chem-Biol Interact 179:60-67.
25. Smith DA and Obach RS (2009) Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267-279.
26. Vishwanathan K, Babalola K, Wang J, Espina R, Yu L, Adedoyin A, Talaat R, Mutlib A, and Scatina J (2009) Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem Res Toxicol 22:311-322.
27. Wong F, Blei AT, Blendis LM, and Thuluvath P (2003) A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hematology 37:182-191.
28. Zmily H, Khan N, Daifallah S, and Ghali J (2011) The potential role for lixivaptan in heart failure and in hyponatremia. Expert Opin Invest Drugs 20:831-848.